Caffeic acid (Synonyms: 咖啡酸)

目录号: HY-N0172 纯度: 99.92%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

Caffeic acid 是 TRPV1 离子通道和 5-脂氧合酶 (5-LO) 的抑制剂。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Caffeic acid Chemical Structure

CAS No. : 331-39-5

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥550	In-stock
100 mg	￥500	In-stock
5 g	￥850	In-stock
10 g		询价
50 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Caffeic acid:

MCE 顾客使用本产品发表的 3 篇科研文献

Caffeic acid 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 TRP Channel 亚型特异性产品:

查看所有亚型

TRPC TRPM TRPV TRPA TRPML

查看 Lipoxygenase 亚型特异性产品:

查看所有亚型

5-LOX 12-LOX 15-LOX

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Caffeic acid is an inhibitor of both TRPV1 ion channel and 5-Lipoxygenase (5-LO).

IC₅₀ & Target

5-LO

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 100 μM Compound: CA	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 26638042]
A549	IC₅₀	0.5 mM Compound: Caffeic acid	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by FMCA assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by FMCA assay	[PMID: 27162124]
A549	IC₅₀	0.7 mM Compound: Caffeic acid	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27162124]
A549	IC₅₀	0.7 mM Compound: Caffeic acid	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by luminescence-based ATP assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by luminescence-based ATP assay	[PMID: 27162124]
AGS	IC₅₀	129 μM Compound: 8	Cytotoxicity against human AGS cells after 96 hrs by MTT assay Cytotoxicity against human AGS cells after 96 hrs by MTT assay	[PMID: 23746477]
B16-F10	IC₅₀	> 100 μM Compound: CA	Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 26638042]
BALB/3T3	IC₅₀	553.8 μM Compound: 12	Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay	[PMID: 10096863]
BMDC	IC₅₀	> 50 μM Compound: 3	Inhibition of LPS-induced IL-12 p40 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA Inhibition of LPS-induced IL-12 p40 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA	[PMID: 25769817]
BMDC	IC₅₀	> 50 μM Compound: 3	Inhibition of LPS-induced IL-6 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA Inhibition of LPS-induced IL-6 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA	[PMID: 25769817]
BMDC	IC₅₀	> 50 μM Compound: 3	Inhibition of LPS-induced TNF-alpha production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA Inhibition of LPS-induced TNF-alpha production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA	[PMID: 25769817]
BMDM	IC₅₀	41 μM Compound: Caffeic acid	Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-base Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-base	[PMID: 31257875]
Caco-2	IC₅₀	> 100 μM Compound: CA	Antiproliferative activity against human Caco2 cells after 72 hrs by MTT assay Antiproliferative activity against human Caco2 cells after 72 hrs by MTT assay	[PMID: 26638042]
EA.hy 926	EC₅₀	12.6 μM Compound: Caffeic acid	Cytoprotective activity against H2O2-induced cytotoxicity in human EAhy926 cells pre-incubated for 24 hrs before H2O2 challenge for 12 hrs by MTT assay Cytoprotective activity against H2O2-induced cytotoxicity in human EAhy926 cells pre-incubated for 24 hrs before H2O2 challenge for 12 hrs by MTT assay	10.1039/C4MD00022F
Erythrocyte	IC₅₀	0.75 mM Compound: 21	Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me	[PMID: 29631958]
Erythrocyte	IC₅₀	0.94 mM Compound: 21	Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet	[PMID: 29631958]
HCT-116	IC₅₀	29.73 μM Compound: 8	Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay	[PMID: 23746477]
HeLa	IC₅₀	2.54 mM Compound: 22, 3,4-dihydroxy-cinnamic acid	Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay	[PMID: 19520580]
HeLa	IC₅₀	44 μg/mL Compound: 2	Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA	[PMID: 19942440]
Hep 3B2	IC₅₀	10 nM Compound: 3, CA	Inhibition of MMP9 in human Hep3B cells using gelatin as substrate Inhibition of MMP9 in human Hep3B cells using gelatin as substrate	[PMID: 23375794]
HT-22	EC₅₀	77.1 μM Compound: 30	Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay	[PMID: 32991171]
HT-29	IC₅₀	> 100 μM Compound: CaA	Growth inhibition of human HT-29 cells after 48 hrs by MTT assay Growth inhibition of human HT-29 cells after 48 hrs by MTT assay	[PMID: 27783972]
HT-29	IC₅₀	27.16 μM Compound: 8	Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay	[PMID: 23746477]
LNCaP	IC₅₀	> 100 μM Compound: 1	Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 24 hrs by WST-1 assay Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 24 hrs by WST-1 assay	[PMID: 24080105]
MCF7	IC₅₀	> 550 μM Compound: Caffeic acid	Cytotoxicity against human MCF7 cells assessed as [3H]-hypoxanthine incorporation after 48 hrs Cytotoxicity against human MCF7 cells assessed as [3H]-hypoxanthine incorporation after 48 hrs	[PMID: 20954722]
MDA-MB-231	IC₅₀	> 100 μM Compound: CaA	Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 27783972]
MOLM-13	IC₅₀	6.4 μM Compound: 15	Antiproliferative activity against human MOLM13 cells by Cell-Titer Glo assay Antiproliferative activity against human MOLM13 cells by Cell-Titer Glo assay	[PMID: 30370766]
MOLM-14	IC₅₀	> 10 μM Compound: 15	Antiproliferative activity against human MOLM14 cells by Cell-Titer Glo assay Antiproliferative activity against human MOLM14 cells by Cell-Titer Glo assay	[PMID: 30370766]
MT4	IC₅₀	> 1 μM Compound: 5	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells by p24 ELISA Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells by p24 ELISA	[PMID: 27676157]
MV4-11	IC₅₀	> 10 μM Compound: 15	Antiproliferative activity against human MV4-11 cells by Cell-Titer Glo assay Antiproliferative activity against human MV4-11 cells by Cell-Titer Glo assay	[PMID: 30370766]
Oocyte	IC₅₀	16.7 μM Compound: Caf-COOH	Antagonist activity at Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents after 30 secs by voltage clamp technique Antagonist activity at Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents after 30 secs by voltage clamp technique	[PMID: 23682762]
P388	GI₅₀	> 25 μg/mL Compound: caffeic acid	Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay	[PMID: 10785435]
PC-12	IC₅₀	75.8 μM Compound: Caffeic acid	Neuroprotection against amyloid beta (25 to 35)-induced cell death in rat PC12 cells preincubated for 3 hrs followed by amyloid beta addition measured after 24 hrs by MTT assay Neuroprotection against amyloid beta (25 to 35)-induced cell death in rat PC12 cells preincubated for 3 hrs followed by amyloid beta addition measured after 24 hrs by MTT assay	[PMID: 29107423]
PC-3	IC₅₀	> 100 μM Compound: CA	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 26638042]
Peritoneal macrophage cell	IC₅₀	> 550 μM Compound: Caffeic acid	Cytotoxicity against mouse peritoneal macrophages assessed as cell viability after 48 hrs by hematocytometer Cytotoxicity against mouse peritoneal macrophages assessed as cell viability after 48 hrs by hematocytometer	[PMID: 20954722]
RAW264.7	EC₅₀	165.295 μM Compound: 1	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells assessed as nitrite accumulation administered 1 hr before LPS challenge and measured after 24 hrs by Griess reagent assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells assessed as nitrite accumulation administered 1 hr before LPS challenge and measured after 24 hrs by Griess reagent assay	[PMID: 18667320]
RAW264.7	EC₅₀	3406 μM Compound: 1	Cytotoxicity against mouse RAW264.7 cells assessed as cell survival after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as cell survival after 24 hrs by MTT assay	[PMID: 18667320]
SH-SY5Y	EC₅₀	33.82 μM Compound: Caffeic acid	Neuroprotection against H2O2-induced cell death in human SH-SY5Y cells preincubated for 6 hrs followed by H2O2 addition and measured after 24 hrs by MTT assay Neuroprotection against H2O2-induced cell death in human SH-SY5Y cells preincubated for 6 hrs followed by H2O2 addition and measured after 24 hrs by MTT assay	[PMID: 30470490]
T47D	IC₅₀	2 nM Compound: Caffeic acid	Antiproliferative activity against human T47D cells after 5 days by MTT assay Antiproliferative activity against human T47D cells after 5 days by MTT assay	[PMID: 23228470]
U-937	CC₅₀	> 2000 μM Compound: 19, CA	Cytotoxicity against human U937 cells after 48 hrs by trypan blue assay Cytotoxicity against human U937 cells after 48 hrs by trypan blue assay	[PMID: 22925447]
U-937	IC₅₀	316.5 μM Compound: 19, CA	Antiproliferative activity against human U937 cells assessed as incorporation of [3H]-methyl-thymidine after 12 hrs by scintillation counting Antiproliferative activity against human U937 cells assessed as incorporation of [3H]-methyl-thymidine after 12 hrs by scintillation counting	[PMID: 22925447]
U-937	EC₅₀	9.9 μM Compound: 5	Cytotoxicity against human U937 cells assessed as reduction in viability incubated for 24 hrs by MTT assay Cytotoxicity against human U937 cells assessed as reduction in viability incubated for 24 hrs by MTT assay	[PMID: 26197161]
Vero	IC₅₀	> 550 μM Compound: Caffeic acid	Cytotoxicity against african green monkey Vero cells assessed as [3H]-hypoxanthine incorporation after 48 hrs Cytotoxicity against african green monkey Vero cells assessed as [3H]-hypoxanthine incorporation after 48 hrs	[PMID: 20954722]

体外研究
(In Vitro)

Caffeic acid 对组胺诱导的反应具有抑制作用，当用于预处理的浓度从 0.1 增加到 1 mM 时，Caffeic acid 的抑制作用逐渐增加，类似于典型的剂量依赖性反应。用 1 mM Caffeic acid 预处理 HEK293T-TRPV1 细胞可显著抑制辣椒素诱导的反应。当使用较低浓度的 Caffeic acid 时，辣椒素诱导反应的抑制作用不太明显。钙成像实验表明，Caffeic acid 孵育可显著抑制组胺敏感的背根神经节 (DRG) 神经元。用 Caffeic acid (1 mM) 预处理导致对组胺应用有反应的 DRG 神经元的百分比从 12.5% 显著降低到 2.1%。用 1 mM Caffeic acid 预处理可显著阻断 TRPA1 表达细胞中异硫氰酸烯丙酯 (AITC) 诱导的细胞内钙增加。Caffeic acid 还能够阻断 AITC 诱导的 TRPA1 激活^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

用 Caffeic acid (500 mg/kg) 预处理的小鼠表现出明显较少的组胺诱导的抓挠 (30.50±10.87 次/1 小时，n=6)。进一步发现，较低剂量的 Caffeic acid (100 mg/kg) 在组胺引起的抓挠中的抗抓挠效果并不显著，尽管似乎有减少的趋势 (49.40±12.35 次/1 h，n=5) . 500 mg/kg Caffeic acid 预处理可显著抑制氯喹诱导的抓挠 (161.6±31.42 次/1 h，n=5)^[1]。
Caffeic acid 显著降低 5-LO mRNA (P<0.01) 在海马中呈剂量依赖性。与缺血再灌注 (I/R) 未处理组相比，I/R-Caffeic acid 组 5-LO 蛋白表达显著降低 (P<0.05 或 P<0.01)，尤其是 I/R- Caffeic acid 组 (50 mg/kg)。与 I/R 未处理组相比，低剂量和高剂量 Caffeic acid 组寻找平台的潜伏期显著缩短，缩短的平台潜伏期在 I/R- Caffeic acid 组 (50 mg/kg) (P<0.01)。低剂量 Caffeic acid 组细胞损伤仍明显，固缩率为 (63.6±2.8) %，而高剂量 Caffeic acid 组海马神经元核固缩明显减少，固缩率为 (13.3±3.0)%^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

180.16

Formula

C₉H₈O₄

CAS 号

331-39-5

性状

固体

颜色

Off-white to light yellow

中文名称

咖啡酸

结构分类

初始来源

微生物

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (555.06 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	5.5506 mL	27.7531 mL	55.5062 mL
5 mM	1.1101 mL	5.5506 mL	11.1012 mL
10 mM	0.5551 mL	2.7753 mL	5.5506 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (13.88 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案二

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (13.88 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
方案三

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (11.55 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.92%

选择批次：

Data Sheet (650 KB) SDS (418 KB)

COA (283 KB) HNMR (120 KB) LCMS (95 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Pradhananga S, et al. Caffeic acid exhibits anti-pruritic effects by inhibition of multiple itch transmission pathways in mice. Eur J Pharmacol. 2015 Sep 5;762:313-21. [Content Brief]

[2]. Liang G, et al. The protective effect of caffeic acid on global cerebral ischemia-reperfusion injury in rats. Behav Brain Funct. 2015 Apr 18;11:18. [Content Brief]

Cell Assay ^[1]	To determine cell viability, MTT assay is performed. HEK293T cells are cultured in 96-well plate at 37°C, a day before so that the confluence of cell is 85 to 90% on the actual day of the experiment. On the day of the experiment the cells are treated with different concentration of Caffeic acid for 10 min. Control cells are treated only with media. After removing supernatant and washing with PBS, MTT reagent (5 mg/mL) is added directly to fresh media. Cells are then incubated at 37°C for additional 4 h followed by draining of the media and overnight storage in dark condition. The next day, DMSO is added to each well and mixed in shaker for 10 min after which plate is read using microplate recorder at 490 nm with a reference wavelength of 620 nm. The relative cell viability (%) is expressed as a percentage relative to the untreated control cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	Rats are divided into five groups: the sham group (n=9), ischemia-reperfusion (I/R) non-treated group (n=9), I/R-Caffeic acid group (10 mg/kg) (n=9), I/R-Caffeic acid group (30 mg/kg) (n=9) and I/R- Caffeic acid group (50 mg/kg) (n=9). In I/R-Caffeic acid groups, the rats are administrated Caffeic acid at 10, 30, 50 mg/kg (prepared with 0.3% sodium carboxymethyl cellulose) by intraperitoneal injection at 30 min prior to ischemia. The sham group and I/R group are treated with an equal volume of 0.3% sodium carboxymethyl cellulose^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Pradhananga S, et al. Caffeic acid exhibits anti-pruritic effects by inhibition of multiple itch transmission pathways in mice. Eur J Pharmacol. 2015 Sep 5;762:313-21. [Content Brief] [2]. Liang G, et al. The protective effect of caffeic acid on global cerebral ischemia-reperfusion injury in rats. Behav Brain Funct. 2015 Apr 18;11:18. [Content Brief]

Caffeic acid 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	5.5506 mL	27.7531 mL	55.5062 mL	138.7655 mL
	5 mM	1.1101 mL	5.5506 mL	11.1012 mL	27.7531 mL
	10 mM	0.5551 mL	2.7753 mL	5.5506 mL	13.8766 mL
	15 mM	0.3700 mL	1.8502 mL	3.7004 mL	9.2510 mL
	20 mM	0.2775 mL	1.3877 mL	2.7753 mL	6.9383 mL
	25 mM	0.2220 mL	1.1101 mL	2.2202 mL	5.5506 mL
	30 mM	0.1850 mL	0.9251 mL	1.8502 mL	4.6255 mL
	40 mM	0.1388 mL	0.6938 mL	1.3877 mL	3.4691 mL
	50 mM	0.1110 mL	0.5551 mL	1.1101 mL	2.7753 mL
	60 mM	0.0925 mL	0.4626 mL	0.9251 mL	2.3128 mL
	80 mM	0.0694 mL	0.3469 mL	0.6938 mL	1.7346 mL
	100 mM	0.0555 mL	0.2775 mL	0.5551 mL	1.3877 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Caffeic acid331-39-5咖啡酸TRP ChannelLipoxygenaseEndogenous MetaboliteTransient receptor potential channelsLOXInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Caffeic acid (Synonyms: 咖啡酸)

Customer Review

Other Forms of Caffeic acid:

MCE 顾客使用本产品发表的 3 篇科研文献

Caffeic acid 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 TRP Channel 亚型特异性产品:

查看 Lipoxygenase 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Caffeic acid 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Caffeic acid (Synonyms: 咖啡酸)

Customer Review

Other Forms of Caffeic acid:

Caffeic acid 相关抗体

MCE 顾客使用本产品发表的 3 篇科研文献

Caffeic acid 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 TRP Channel 亚型特异性产品:

查看 Lipoxygenase 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Caffeic acid 相关抗体:

摩尔计算器

稀释计算器

Caffeic acid 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z